A Phase 2 interventional study of Matrix Transdermal Fentanyl/CHADD Drug Delivery System and Placebo Patch in Pain, sponsored by ZARS Pharma Inc.. Terminated at 15 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-06-05.
Sponsored by ZARS Pharma Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,283 studies in Chronic Pain with a site in United States — 258 open to participants now, 349 under way, 7 of them phase 3. Chronic Pain · United States.
Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 355th largest by enrollment of the 1,092 interventional ones that give a count, is one of 17 that started in 2006, is one of 87 in phase 2, and was the 30th registered.
3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
Browse Chronic Pain studies →258 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:
University of Oklahoma · Sites in United States
Ages 18–120
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18+ · Women only
University of Massachusetts, Boston · Sites in United States
Ages 65+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 487 Chronic Pain studies recruiting now, 240 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 112 · Phase 3 72 · Phase 4 50
First in 1992; this study’s year is marked. 17 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 60 across the 1,092 interventional studies, 100 across the 189 observational. Of the 847 that completed or were terminated, 386 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
209 of 1,283 have an industry lead sponsor. The 10 most frequent:
ZARS Pharma Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
ZARS Pharma Inc. has 4 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
140 of the studies in Chronic Pain with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05703178Phase 3Northwestern UniversityWeb-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | 2026-11-30 |
| NCT06091202Phase 3Oregon Health and Science UniversityTele-Collaborative Outreach to Rural Patients With Chronic Pain | 2027-05-01 |
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT03984565Staci Gruber, Ph.D.PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product | 2026-11 |
Add all 140 to your calendar (.ics) → With an account.
Among the 1,283 studies in Chronic Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multi-center study to evaluate the efficacy of CHADD (Controlled Heat-Assisted Drug Delivery) applied over a 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch for the treatment of breakthrough pain in adult patients with moderate to severe non-malignant chronic pain. The open-label study arm will last up to 12 days. The double-blind arm will last up to 15 days. Eligible patients who complete the open-label arm will be allowed to enroll in the double-blind study arm.
ZARS Pharma is developing a Matrix Transdermal Fentanyl/CHADD (Controlled Heat-Assisted Drug Delivery) Drug Delivery System to be used for the treatment of chronic and breakthrough pain. The Matrix Transdermal Fentanyl/CHADD Drug Delivery System has been designed to provide long-term delivery of fentanyl for the treatment of chronic pain as well as intermittent increases in fentanyl concentrations for the treatment of breakthrough pain. Breakthrough pain is defined as a transitory exacerbation of pain that occurs on a background of otherwise stable pain in a patient receiving chronic opioid therapy.
Matrix Transdermal Fentanyl/CHADD Drug Delivery System has 2 components: a matrix transdermal fentanyl patch (the ZR-02-01 patch in doses of 25, 50, 75 and 100 mcg/hr) with corresponding thin film dressing (ie, overlay) and the CHADD (Controlled Heat-Assisted Drug Delivery).
The matrix transdermal fentanyl patch provides a continuous delivery of fentanyl over 72 hours, in a manner similar to Duragesic®. During a breakthrough pain episode, a CHADD unit is placed over (adhered to) the matrix transdermal fentanyl patch. The CHADD is a thin patch-like chemical heating device that generates a controlled level of heat for approximately 15-20 minutes. The application of heat delivers increased amounts of fentanyl when applied over the ZR-02-01 matrix transdermal fentanyl patch.
3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
This study's enrollment of 109 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Browse Chronic Pain studies →ZARS Pharma Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Compared within Chronic Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)
Drug: Matrix Transdermal Fentanyl/CHADD Drug Delivery System
placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch
Drug: Placebo Patch
Patch applied every 3 days for 15 days
Also known as: ZR-02-01, Fentanyl Transdermal Matrix Patch
Placebo patch applied every 3 days for 15 days
Also known as: Placebo Matrix Patch
Patient's rating of pain intensity (NRS), the patient's evaluation of pain relief using a 5-point verbal rating scale (VRS), and the patient's global satisfaction assessment.
Efficacy will be evaluated by the patient's rating of pain intensity using an 11-point numerical rating scale (NRS), the patient's evaluation of pain relief using a 5-point verbal rating scale (VRS), and the patient's global satisfaction assessment.
Time frame: 0, 15, 20, 60 minutes
Adhesion assessment
An adhesion assessment will be conducted by the patient at each CHADD removal.
Time frame: 3 days
Pain Relief
Patient's evaluation of pain relief using a 5-point verbal rating scale (VRS)
Time frame: 15, 30, 60 minutes
Patient's Global Satisfaction Assessment
Patients completed a global satisfaction assessment 60 minutes after CHADD application. Patients were asked to assess their overall satisfaction with the CHADD throughout the 60 minute application period for the treatment of their breakthrough pain using the following 5-point scale: 0=not satisfied, 1=somewhat satisfied, 2=moderately satisfied, 3=very satisfied, and 4=completely satisfied.
Time frame: 60 minutes
Number of participants with adverse events
The frequency of adverse events, severity, and relationship to study drug was recorded.
Time frame: 15 days
The record gives a start of Jan 2006, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.